TNF biology, pathogenic mechanisms and emerging therapeutic strategies

Nature Reviews Rheumatology

Volumn 12, Issue 1, 2016, Pages 49-62

  Kalliolias, George D ^a   Ivashkiv, Lionel B ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGONISTIC TUMOR NECROSIS FACTOR RECEPTOR 1 SPECIFIC ANTIBODY; COMPLEX IIA PROTEIN; COMPLEX IIB PROTEIN; COMPLEX IIC PROTEIN; MDS 5541; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 1 ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1 SILENCER; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; XENP 345; XPRO 1595;

ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL MIGRATION; CHROMATIN; CHROMATIN MODIFICATION; CYTOKINE PRODUCTION; DNA METHYLATION; EPIGENETICS; GENE; GENE EXPRESSION; HOMEOSTASIS; HUMAN; HYPERNOCICEPTION; IMMUNOGENICITY; LEUKOCYTE ROLLING; NOCICEPTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; INFLAMMATION; METABOLISM; PROCEDURES;

GENE EXPRESSION REGULATION; GENETIC THERAPY; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84954197918     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2015.169     Document Type: Article

References (147)

1. Aggarwal, B. B., Gupta, S. C. & Kim, J. H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119, 651-665 (2012).
2. Feldmann, M. Translating molecular insights in autoimmunity into effective therapy. Annu. Rev. Immunol. 27, 1-27 (2009).
3. Cerami, A. The value of failure: the discovery of TNF and its natural inhibitor erythropoietin. J. Intern. Med. 269, 8-15 (2011).
4. Monaco, C., Nanchahal, J., Taylor, P. & Feldmann, M. Anti-TNF therapy: past, present and future. Int. Immunol. 27, 55-62 (2015).
5. Lee, R. A. & Eisen, D. B. Treatment of hidradenitis suppurativa with biologic medications. J. Am. Acad. Dermatol. 73, S82-88 (2015).
6. Dorner, T. & Kay, J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat. Rev. Rheumatol. http://dx.doi.org/10.1038/nrrheum.2015.110 (2015).
7. Karampetsou, M. P., Liossis, S. N. & Sfikakis, P. P. TNF-antagonists beyond approved indications: stories of success and prospects for the future. QJM 103, 917-928 (2010).
8. Issuree, P. D. et al. iRHOM2 is a critical pathogenic mediator of inflammatory arthritis. J. Clin. Invest. 123, 928-932 (2013).
9. Horiuchi, K. et al. Cutting edge: TNF-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J. Immunol. 179, 2686-2689 (2007).
10. Locksley, R. M., Killeen, N. & Lenardo, M. J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487-501 (2001).
11. Grell, M. et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83, 793-802 (1995).
12. Probert, L. TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects. Neuroscience 302, 2-22 (2015).
13. Pasparakis, M. & Vandenabeele, P. Necroptosis and its role in inflammation. Nature 517, 311-320 (2015).
14. Brenner, D., Blaser, H. & Mak, T. W. Regulation of tumour necrosis factor signalling: live or let die. Nat. Rev. Immunol. 15, 362-374 (2015).
15. Bianchi, K. & Meier, P. A tangled web of ubiquitin chains: breaking news in TNF-R1 signaling. Mol. Cell 36, 736-742 (2009).
16. Haas, T. L. et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol. Cell 36, 831-844 (2009).
17. Rahighi, S. et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-B activation. Cell 136, 1098-1109 (2009).
18. Dynek, J. N. et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J. 29, 4198-4209 (2010).
19. Linkermann, A. & Green, D. R. Necroptosis. N. Engl. J. Med. 370, 455-465 (2014).
20. Chan, F. K., Luz, N. F. & Moriwaki, K. Programmed necrosis in the cross talk of cell death and inflammation. Annu. Rev. Immunol. 33, 79-106 (2015).
21. Micheau, O. & Tschopp, J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114, 181-190 (2003).
22. Wang, L., Du, F. & Wang, X. TNF-induces two distinct caspase-8 activation pathways. Cell 133, 693-703 (2008).
23. Sun, L. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213-227 (2012).
24. Kumari, S. & Pasparakis, M. Epithelial cell death and inflammation in skin. Curr. Top. Microbiol. Immunol. http://dx.doi.org/10.1007/82-2015-466 (2015).
25. Dannappel, M. et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 513, 90-94 (2014).
26. Takahashi, N. et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature 513, 95-99 (2014).
27. Silke, J., Rickard, J. A. & Gerlic, M. The diverse role of RIP kinases in necroptosis and inflammation. Nat. Immunol. 16, 689-697 (2015).
28. Harhaj, E. W. & Dixit, V. M. Regulation of NF. ÈB by deubiquitinases. Immunol. Rev. 246, 107-124 (2012).
29. Maruyama, H. et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223-226 (2010).
30. Zhu, G., Wu, C. J., Zhao, Y. & Ashwell, J. D. Optineurin negatively regulates TNF ¿-induced NF. ÈB activation by competing with NEMO for ubiquitinated RIP. Curr. Biol. 17, 1438-1443 (2007).
31. Shibata, Y. et al. p47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO. Nat. Commun. 3, 1061 (2012).
32. Verhelst, K. et al. A20 inhibits LUBAC-mediated NF. ÈB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J. 31, 3845-3855 (2012).
33. Tokunaga, F. et al. Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF. ÈB regulation. EMBO J. 31, 3856-3870 (2012).
34. Keusekotten, K. et al. OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1.linked polyubiquitin. Cell 153, 1312-1326 (2013).
35. Ahmed, N. et al. The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat. Immunol. 12, 1176-1183 (2011).
36. Shembade, N. et al. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat. Immunol. 9, 254-262 (2008).
37. Li, L. et al. Localization of A20 to a lysosomeassociated compartment and its role in NF ÈB signaling. Biochim. Biophys. Acta 1783, 1140-1149 (2008).
38. Li, S., Wang, L., Berman, M. A., Zhang, Y. & Dorf, M. E. RNAi screen in mouse astrocytes identifies phosphatases that regulate NF. ÈB signaling. Mol. Cell 24, 497-509 (2006).
39. Li, H. Y. et al. Deactivation of the kinase IKK by CUEDC2 through recruitment of the phosphatase PP1. Nat. Immunol. 9, 533-541 (2008).
40. Zuo, S. et al. 14.3.3 epsilon dynamically interacts with key components of mitogen-activated protein kinase signal module for selective modulation of the TNF-¿-induced time course-dependent NF. ÈB activity. J. Proteome Res. 9, 3465-3478 (2010).
41. Chew, J. et al. WIP1 phosphatase is a negative regulator of NF. ÈB signalling. Nat. Cell Biol. 11, 659-666 (2009).
42. Hoffmann, A., Levchenko, A., Scott, M. L. & Baltimore, D. The I ÈB.NF. ÈB signaling module: temporal control and selective gene activation. Science 298, 1241-1245 (2002).
43. Shih, V. F. et al. Kinetic control of negative feedback regulators of NF. ÈB/RelA determines their pathogenand cytokine-receptor signaling specificity. Proc. Natl Acad. Sci. USA 106, 9619-9624 (2009).
44. Kearns, J. D., Basak, S., Werner, S. L., Huang, C. S. & Hoffmann, A. I ÈB Ã provides negative feedback to control NF. ÈB oscillations, signaling dynamics, and inflammatory gene expression. J. Cell Biol. 173, 659-664 (2006).
45. Nelson, D. E. et al. Oscillations in NF. ÈB signaling control the dynamics of gene expression. Science 306, 704-708 (2004).
46. Ashall, L. et al. Pulsatile stimulation determines timing and specificity of NF. ÈB-dependent transcription. Science 324, 242-246 (2009).
47. Tay, S. et al. Single-cell NF. ÈB dynamics reveal digital activation and analogue information processing. Nature 466, 267-271 (2010).
48. Lee, A. et al. Tumor necrosis factor ¿ induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 65, 928-938 (2013).
49. Justus, S. J. & Ting, A. T. Cloaked in ubiquitin, a killer hides in plain sight: the molecular regulation of RIPK1. Immunol. Rev. 266, 145-160 (2015).
50. Tokunaga, F. et al. SHARPIN is a component of the NF. ÈB-activating linear ubiquitin chain assembly complex. Nature 471, 633-636 (2011).
51. Ikeda, F. et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF. ÈB activity and apoptosis. Nature 471, 637-641 (2011).
52. Gerlach, B. et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471, 591-596 (2011).
53. Kumari, S. et al. Sharpin prevents skin inflammation by inhibiting TNFR1.induced keratinocyte apoptosis. eLIFE 3, e03422 (2014).
54. Rickard, J. A. et al. TNFR1.dependent cell death drives inflammation in Sharpin-deficient mice. eLIFE 3, e03464 (2014).
55. Onizawa, M. et al. The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. Nat. Immunol. 16, 618-627 (2015).
56. Newton, K. et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 343, 1357-1360 (2014).
57. Dillon, C. P. et al. RIPK1 blocks early postnatal lethality mediated by caspase.8 and RIPK3. Cell 157, 1189-1202 (2014).
58. Rickard, J. A. et al. RIPK1 regulates RIPK3.MLKLdriven systemic inflammation and emergency hematopoiesis. Cell 157, 1175-1188 (2014).
59. Zimmermann, M. et al. Chromatin remodelling and autocrine TNF ¿ are required for optimal interleukin.6 expression in activated human neutrophils. Nat. Commun. 6, 6061 (2015).
60. Smale, S. T., Tarakhovsky, A. & Natoli, G. Chromatin contributions to the regulation of innate immunity. Annu. Rev. Immunol. 32, 489-511 (2014).
61. Ostuni, R. et al. Latent enhancers activated by stimulation in differentiated cells. Cell 152, 157-171 (2013).
62. Nakano, K., Whitaker, J. W., Boyle, D. L., Wang, W. & Firestein, G. S. DNA methylome signature in rheumatoid arthritis. Ann. Rheum. Dis. 72, 110-117 (2013).
63. Ai, R. et al. DNA methylome signature in synoviocytes from patients with early rheumatoid arthritis compared to synoviocytes from patients with longstanding rheumatoid arthritis. Arthritis Rheumatol. 67, 1978-1980 (2015).
64. Nakano, K., Boyle, D. L. & Firestein, G. S. Regulation of DNA methylation in rheumatoid arthritis synoviocytes. J. Immunol. 190, 1297-1303 (2013).
65. Haseeb, A., Makki, M. S. & Haqqi, T. M. Modulation of ten-eleven translocation 1 (TET1), isocitrate dehydrogenase (IDH) expression, ¿-ketoglutarate ( ¿.KG), and DNA hydroxymethylation levels by interleukin.1 À in primary human chondrocytes. J. Biol. Chem. 289, 6877-6885 (2014).
66. Xue, J. et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40, 274-288 (2014).
67. Donlin, L. T., Jayatilleke, A., Giannopoulou, E. G., Kalliolias, G. D. & Ivashkiv, L. B. Modulation of TNFinduced macrophage polarization by synovial fibroblasts. J. Immunol. 193, 2373-2383 (2014).
68. Yarilina, A., Park-Min, K. H., Antoniv, T., Hu, X. & Ivashkiv, L. B. TNF activates an IRF1.dependent autocrine loop leading to sustained expression of chemokines and STAT1.dependent type I interferonresponse genes. Nat. Immunol. 9, 378-387 (2008).
69. Hao, S. & Baltimore, D. The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nat. Immunol. 10, 281-288 (2009).
70. Yarilina, A., Xu, K., Chen, J. & Ivashkiv, L. B. TNF activates calcium-nuclear factor of activated T cells (NFAT)c1 signaling pathways in human macrophages. Proc. Natl Acad. Sci. USA 108, 1573-1578 (2011).
71. Rosengren, S., Corr, M., Firestein, G. S. & Boyle, D. L. The JAK inhibitor CP.690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann. Rheum. Dis. 71, 440-447 (2012).
72. Ghisletti, S. et al. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev. 23, 681-693 (2009).
73. Hargreaves, D. C., Horng, T. & Medzhitov, R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 138, 129-145 (2009).
74. Cronk, J. C. et al. Methyl-CpG binding protein 2 regulates microglia and macrophage gene expression in response to inflammatory stimuli. Immunity 42, 679-691 (2015).
75. Sohn, C. et al. Prolonged tumor necrosis factor ¿ primes fibroblast-like synoviocytes in a gene-specific manner by altering chromatin. Arthritis Rheumatol. 67, 86-95 (2015).
76. Park, S. H., Park-Min, K. H., Chen, J., Hu, X. & Ivashkiv, L. B. Tumor necrosis factor induces GSK3 kinase-mediated cross-tolerance to endotoxin in macrophages. Nat. Immunol. 12, 607-615 (2011).
77. Monticelli, S. & Natoli, G. Short-term memory of danger signals and environmental stimuli in immune cells. Nat. Immunol. 14, 777-784 (2013).
78. Pasparakis, M., Alexopoulou, L., Episkopou, V. & Kollias, G. Immune and inflammatory responses in TNF ¿-deficient mice: a critical requirement for TNF ¿ in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184, 1397.1411 (1996).
79. Marino, M. W. et al. Characterization of tumor necrosis factor-deficient mice. Proc. Natl Acad. Sci. USA 94, 8093-8098 (1997).
80. Liu, J. et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. 4, 78-83 (1998).
81. Sugarman, B. J. et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230, 943-945 (1985).
82. Braumuller, H. et al. T.helper-1.cell cytokines drive cancer into senescence. Nature 494, 361-365 (2013).
83. Arnett, H. A. et al. TNF ¿ promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 4, 1116-1122 (2001).
84. Papathanasiou, S. et al. Tumor necrosis factor- ¿ confers cardioprotection through ectopic expression of keratins K8 and K18. Nat. Med. 21, 1076-1084 (2015).
85. Zhao, Y. P. et al. Progranulin protects against osteoarthritis through interacting with TNF- ¿ and À-catenin signalling. Ann. Rheum. Dis. 74, 2244-2253 (2014).
86. Bluml, S. et al. Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum. 62, 1608-1619 (2010).
87. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53, 457-465 (1999).
88. Robinson, W. H., Genovese, M. C. & Moreland, L. W. Demyelinating and neurologic events reported in association with tumor necrosis factor ¿ antagonism: by what mechanisms could tumor necrosis factor ¿ antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis Arthritis Rheum. 44, 1977-1983 (2001).
89. Inglis, J. J. et al. Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. Arthritis Rheum. 56, 4015-4023 (2007).
90. Boettger, M. K. et al. Antinociceptive effects of tumor necrosis factor ¿ neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target. Arthritis Rheum. 58, 2368-2378 (2008).
91. Richter, F. et al. Tumor necrosis factor causes persistent sensitization of joint nociceptors to mechanical stimuli in rats. Arthritis Rheum. 62, 3806-3814 (2010).
92. Boettger, M. K. et al. Spinal tumor necrosis factor alpha neutralization reduces peripheral inflammation and hyperalgesia and suppresses autonomic responses in experimental arthritis: a role for spinal tumor necrosis factor alpha during induction and maintenance of peripheral inflammation. Arthritis Rheum. 62, 1308-1318 (2010).
93. Konig, C., Zharsky, M., Moller, C., Schaible, H. G. & Ebersberger, A. Involvement of peripheral and spinal tumor necrosis factor alpha in spinal cord hyperexcitability during knee joint inflammation in rats. Arthritis Rheumatol. 66, 599-609 (2014).
94. Hess, A. et al. Blockade of TNF- ¿ rapidly inhibits pain responses in the central nervous system. Proc. Natl Acad. Sci. USA 108, 3731-3736 (2011).
95. Carswell, E. A. et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 72, 3666-3670 (1975).
96. Beutler, B. & Cerami, A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 320, 584-588 (1986).
97. Elinav, E. et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 13, 759-771 (2013).
98. Zhao, X. et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J. Clin. Invest. 122, 4094-4104 (2012).
99. Hu, X. et al. Transmembrane TNF- ¿ promotes suppressive activities of myeloid-derived suppressor cells via TNFR2. J. Immunol. 192, 1320-1331 (2014).
100. Haudek, S. B., Taffet, G. E., Schneider, M. D. & Mann, D. L. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J. Clin. Invest. 117, 2692-2701 (2007).
101. Skeoch, S. & Bruce, I. N. Atherosclerosis in rheumatoid arthritis: is it all about inflammation Nat. Rev. Rheumatol. 11, 390-400 (2015).
102. Verjee, L. S. et al. Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target. Proc. Natl Acad. Sci. USA 110, E928-E937 (2013).
103. Feldmann, M. & Maini, R. N. Perspectives from masters in rheumatology and autoimmunity: can we get closer to a cure for rheumatoid arthritis Arthritis Rheumatol. 67, 2283-2291 (2015).
104. Smith, J. A. & Kauffman, C. A. Endemic fungal infections in patients receiving tumour necrosis factor-inhibitor therapy. Drugs 69, 1403-1415 (2009).
105. Deepak, P. et al. Tcell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factoralpha (TNF-) inhibitors: results of the REFURBISH study. Am. J. Gastroenterol. 108, 99-105 (2013).
106. Fischer, J. A. et al. Combined inhibition of tumor necrosis factor and interleukin17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol. 67, 51-62 (2015).
107. Genovese, M. C. et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50, 1412-1419 (2004).
108. Weinblatt, M. et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 66, 228-234 (2007).
109. Schmidt, E. M. et al. Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures. Arthritis Rheum. 65, 2262-2273 (2013).
110. Zettlitz, K. A. et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor onespecific antibody. MAbs 2, 639-647 (2010).
111. Richter, F. et al. Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity. PLoS ONE 8, e72156 (2013).
112. McCann, F. E. et al. Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol. 66, 2728-2738 (2014).
113. Steeland, S. et al. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. J. Biol. Chem. 290, 4022-4037 (2015).
114. Steed, P. M. et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301, 1895-1898 (2003).
115. Zalevsky, J. et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J. Immunol. 179, 1872-1883 (2007).
116. Shibata, H. et al. Creation and Xray structure analysis f the tumor necrosis factor receptor-1selective mutant of a tumor necrosis factor-antagonist. J. Biol. Chem. 283, 998-1007 (2008).
117. Kitagaki, M. et al. Novel TNF-receptor 1 antagonist treatment attenuates arterial inflammation and intimal hyperplasia in mice. J. Atheroscler. Thromb. 19, 36-46 (2012).
118. Fischer, R. et al. A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLoS ONE 6, e27621 (2011).
119. Tang, W. et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 332, 478-484 (2011).
120. Durez, P. et al. Therapeutic vaccination with TNFKinoid in TNF antagonist-resistant rheumatoid arthritis: a Phase II randomized, controlled clinical trial. PLoS ONE 9, e113465 (2014).
121. Rao, P. et al. IB acts to inhibit and activate gene expression during the inflammatory response. Nature 466, 1115-1119 (2010).
122. Brown, J. D. et al. NFB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol. Cell 56, 219-231 (2014).
123. Yarilina, A., Xu, K., Chan, C. & Ivashkiv, L. B. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 64, 3856-3866 (2012).
124. Klein, K., Kabala, P. A. & Grabiec, A. M. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2014-205809 (2014).
125. Grabiec, A. M., Korchynskyi, O., Tak, P. P. & Reedquist, K. A. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL6 production by accelerating mRNA decay. Ann. Rheum. Dis. 71, 424-431 (2012).
126. Pandis, I. et al. Identification of microRNA221/222 and microRNA3233p association with rheumatoid arthritis via predictions using the human tumour necrosis factor transgenic mouse model. Ann. Rheum. Dis. 71, 1716-1723 (2012).
127. Trenkmann, M. et al. Tumor necrosis factor-induced microRNA18a activates rheumatoid arthritis synovial fibroblasts through a feedback loop in NFB signaling. Arthritis Rheum. 65, 916-927 (2013).
128. Rapicavoli, N. A. et al. A mammalian pseudogene lncRNA at the interface of inflammation and antiinflammatory therapeutics. eLIFE 2, e00762 (2013).
129. Ermann, J., Rao, D. A., Teslovich, N. C., Brenner, M. B. & Raychaudhuri, S. Immune cell profiling to guide therapeutic decisions in rheumatic diseases. Nat. Rev. Rheumatol. 11, 541-551 (2015).
130. Plant, D., Wilson, A. G. & Barton, A. Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat. Rev. Rheumatol. 10, 329-337 (2014).
131. Shembade, N., Pujari, R., Harhaj, N. S., Abbott, D. W. & Harhaj, E. W. The kinase IKK inhibits activation of the transcription factor NFB by phosphorylating the regulatory molecule TAX1BP1. Nat. Immunol. 12, 834-843 (2011).
132. Shembade, N., Parvatiyar, K., Harhaj, N. S. & Harhaj, E. W. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NFB signalling. EMBO J. 28, 513-522 (2009).
133. Bohgaki, M. et al. Involvement of Ymer in suppression of NFB activation by regulated interaction with lysine-63linked polyubiquitin chain. Biochim. Biophys. Acta 1783, 826-837 (2008).
134. Ma, A. & Malynn, B. A. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat. Rev. Immunol. 12, 774-785 (2012).
135. Wertz, I. E. et al. Deubiquitination and ubiquitin ligase domains of A20 downregulate NFB signalling. Nature 430, 694-699 (2004).
136. Bremm, A., Freund, S. M. & Komander, D. Lys11linked ubiquitin chains adopt compact conformations and are preferentially hydrolyzed by the deubiquitinase Cezanne. Nat. Struct. Mol. Biol. 17, 939-947 (2010).
137. Fiil, B. K. et al. OTULIN restricts Met1linked ubiquitination to control innate immune signaling. Mol. Cell 50, 818-830 (2013).
138. Elliott, P. R. et al. Molecular basis and regulation of OTULIN-LUBAC interaction. Mol. Cell 54, 335-348 (2014).
139. Schaeffer, V. et al. Binding of OTULIN to the PUB domain of HOIP controls NFB signaling. Mol. Cell 54, 349-361 (2014).
140. Bignell, G. R. et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet. 25, 160-165 (2000).
141. Sato, Y. et al. Structures of CYLD USP with Met1-or Lys63linked diubiquitin reveal mechanisms for dual specificity. Nat. Struct. Mol. Biol. 22, 222-229 (2015).
142. Xiao, N. et al. Ubiquitin-specific protease 4 (USP4) targets TRAF2 and TRAF6 for deubiquitination and inhibits TNF-induced cancer cell migration. Biochem. J. 441, 979-986 (2012).
143. Liang, J. et al. MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NFB signaling. J. Exp. Med. 207, 2959-2973 (2010).
144. Matsushita, K. et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 458, 1185-1190 (2009).
145. McCoy, M. K. et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. 26, 9365-9375 (2006).
146. McAlpine, F. E. et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol. Dis. 34, 163-177 (2009).
147. Sama, D. M. et al. Inhibition of soluble tumor necrosis factor ameliorates synaptic alterations and Ca2+ dysregulation in aged rats. PLoS ONE 7, e38170 (2012).